Pediatric Hodgkin Lymphoma Differential Diagnoses
- Author: Pedro A de Alarcon, MD; Chief Editor: Robert J Arceci, MD, PhD more...
Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood. Jun 15 2005;105(12):4553-60. [Medline].
Arya LS, Dinand V. Current strategies in the treatment of childhood Hodgkins disease. Indian Pediatr. Nov 2005;42(11):1115-28. [Medline].
Percy CL, Smith MA, Linet M, et al. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995: Lymphomas and Reticuloendothelial Neoplasms [Surveillance, Epidemiology, and End Results Web site]. November 5, 1999. National Cancer Institute: Surveillance Epidemiology and End Results. Available at http://www.seer.cancer.gov.
Robertson VL, Anderson CS, Keller FG, et al. Role of FDG-PET in the Definition of Involved-Field Radiation Therapy and Management for Pediatric Hodgkin's Lymphoma. Int J Radiat Oncol Biol Phys. Jun 1 2011;80(2):324-32. [Medline].
Harris NL. Hodgkin's disease: classification and differential diagnosis. Mod Pathol. Feb 1999;12(2):159-75. [Medline].
Kuppers R, Yahalom J, Josting A. Advances in biology, diagnostics, and treatment of Hodgkin's disease. Biol Blood Marrow Transplant. Jan 2006;12(1 Suppl 1):66-76. [Medline].
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition. Vol 2. 4th ed. Lyon, France: IARC Press; 2008.
Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. Jan 2009;9(1):15-27. [Medline].
Ng AK, Mauch PM. Late effects of Hodgkin's disease and its treatment. Cancer J. Mar-Apr 2009;15(2):164-8. [Medline].
Cheson BD, Bartlett NL. Hodgkin Lymphoma: New Drug Breakthroughs. Medscape News Today. Available at http://www.medscape.com/viewarticle/733776. Accessed September 18, 2011.
Al-Rahawan MM, A de Alarcón PA. Gemcitabine and vinorelbine therapy for patients with Hodgkin lymphoma. Pediatric Health. Dec 2009;3(6):525-32.
Shankar A, Visaduraki M, Hayward J, Morland B, McCarthy K, Hewitt M. Clinical outcome in children and adolescents with Hodgkin lymphoma after treatment with chemotherapy alone - The results of the United Kingdom HD3 national cohort trial. Eur J Cancer. Jun 22 2011;[Medline].
Küppers R. Molecular biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009;491-6. [Medline].
Glaser SL, Clarke CA, Nugent RA, Stearns CB, Dorfman RF. Social class and risk of Hodgkin's disease in young-adult women in 1988-94. Int J Cancer. Mar 1 2002;98(1):110-7. [Medline].
Deutsch YE, Tadmor T, Podack ER, Rosenblatt JD. CD30: an important new target in hematologic malignancies. Leuk Lymphoma. Sep 2011;52(9):1641-54. [Medline].
Böll B, Bredenfeld H, Görgen H, et al. Phase II study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. Sep 13 2011;[Medline].
Straus DJ, Johnson JL, LaCasce AS, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. May 19 2011;117(20):5314-20. [Medline].

